Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active…
An institutional-grade, numbers-driven thesis on DNTH — generated on demand from live fundamentals, scores and forecast.
Member feature · 7-day free trial · no charge today · cancel anytime
As of August 8, 2026, TradersQuant's model rates Dianthus Therapeutics, Inc. (DNTH) 49/100 with a 12-month base-case forecast of $124.18 — +14.0% versus the current price of $108.92. Dianthus Therapeutics, Inc. trades at $108.92 in the Healthcare sector, with a market capitalisation of $4.55B. The score blends valuation, growth, earnings quality and momentum into a single grade.
The 12-month analyst consensus price target for DNTH is $124.18, implying +14.0% versus the current price. The model's 12-month scenario range runs from $139.00 (bear) to $157.94 (bull), with a base case of $147.35.
On the fundamentals, Dianthus Therapeutics shows a P/E of -837.8, trailing revenue of $2.0M, revenue growth of -67.3% YoY. This page also tracks DNTH's short interest, institutional (smart-money) positioning and the options market — the same cross-signal view institutions watch.
DNTH currently carries a TradersQuant composite score of 49/100, which we read as a cautious signal. The Wall-Street analyst consensus is "Buy". Our 12-month price target of $124.18 implies +14.0% from $108.92. This is research, not financial advice — always combine it with your own judgement.
The analyst consensus price target for DNTH is $124.18, about +14.0% versus the latest price of $108.92. Consensus is based on 11 analysts.
TradersQuant's 12-month model forecast for DNTH is a base case of $147.35, ranging from $139.00 (bear) to $157.94 (bull), an expected return of +35.3%. Forecasts are model estimates, not guarantees.
The TradersQuant price prediction for DNTH over the next 12 months is $147.35 in the base case (bear $139.00, bull $157.94), versus today's price of $108.92. Unlike black-box prediction sites, every TradersQuant call is logged at the price and date it was made and graded publicly against the S&P 500.
We deliberately don't publish 2030 price predictions for DNTH — no model can honestly forecast a single stock five-plus years out, and sites that do are guessing. TradersQuant focuses on a rigorous 12-month bull/base/bear range, refreshed continuously and graded on our public track record.
TradersQuant estimates DNTH's fair value at $124.18, implying +14.0% of expected upside versus the current price.
Dianthus Therapeutics does not currently pay a dividend.
Data and model outputs are for research only and are not financial advice. Figures update continuously.
